Clinical Research Study

 
News Articles for Clinical Research Study top ^
Alkermes plc (NASDAQ: ALKS) today announced the initiation of FORWARD-5, the third of three core efficacy studies planned in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). The study will evaluate the efficacy and safety of ALKS 5461 in patients suffering from MDD who have had an inadequate response to commonly prescribed drugs for depression, including selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Approximately two-thirds of patients who are diagnosed with MDD do not adequately respond to initial antidepressant therapy.
Sign-up for Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder investment picks
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 8700, a novel monomethyl fumarate (MMF) molecule in development for the treatment of multiple sclerosis (MS). The randomized, double-blind study will evaluate the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups in approximately 125 healthy volunteers.
Sign-up for Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 8700 for Treatment of Multiple Sclerosis investment picks
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 7106, a proprietary, novel, oral, small-molecule drug candidate for the treatment of pain.
Sign-up for Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain investment picks
2014/9/4
SoundCure, a medical device company whose mission is to revolutionize the treatment of tinnitus, today announced the results of a randomized, multi-center clinical study that found S-Tones® to be effective at quiet volumes and to be more effective than broadband noise in the reduction of tinnitus, a condition often called, “ringing in the ears.” The study, conducted by leading tinnitus researchers at three top audiology centers, and led by internationally renowned Dr.
Sign-up for SoundCure Announces Results of Randomized Clinical Study: S-Tones Found to be More Effective Than Broadband Noise in Reducing Tinnitus investment picks
Company's research partner, Trauma Research, LLC will present key clinical validation data from a prospective trial utilizing the RedoxSYS™ Diagnostic System and oxidation-reduction potential (ORP) ENGLEWOOD, Colo.
Sign-up for Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting investment picks
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers, today announced dosing of the first patient in its Phase 2 clinical study of ETC-1002 in patients with hypercholesterolemia and hypertension, ETC-1002-014.
Sign-up for Esperion Therapeutics Announces Initiation of a Phase 2 Clinical Study of ETC-1002 in Patients with Hypercholesterolemia and Hypertension investment picks
Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published online ahead of print in the Journal of Clinical Oncology .
Sign-up for Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate investment picks
2014/8/7
PhotoMedex, Inc. (NasdaqGS and TASE:PHMD) today announced that a new independent clinical study demonstrated a substantial reduction in hair regrowth following use of no!no! Hair using proprietary Thermicon™ technology.
Sign-up for New Independent Clinical Study of no!no! Hair Shows Substantial and Statistically Significant Reduction in Hair Regrowth on a Range of Skin Types and Hair Colors investment picks
OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, yesterday hosted a webcast presenting outstanding interim six-month results from a Phase 2 study of its long-acting human growth hormone product Lagova to treat pediatric growth hormone deficiency disorder (GHD). During the webcast, Dr.
Sign-up for Strong Data from Lagova™ Phase II Clinical Study Presented during Webcast investment picks
- Amended Design Expedites Phase 1/2 Trial of Heat's Immuno-Therapy Bladder Cancer Product Candidate – - Provides Accelerated Timeline to Phase 2 Results - DURHAM, N.C., Aug.
Sign-up for Heat Biologics Amends Bladder Cancer Protocol for Early Advancement Into Phase 2 Clinical Studies investment picks
Long-Acting VRS-317 Efficacy and Safety Comparable to Daily Growth Hormone Therapies CHICAGO, June 23, 2014 (GLOBE NEWSWIRE) -- Versartis, Inc. (Nasdaq:VSAR) , an endocrine-focused biopharmaceutical company that is developing a novel, long-acting form of recombinant human growth hormone (rhGH), today presented positive Phase 2a data from its six month clinical trial demonstrating the safety and efficacy of VRS-317 in the treatment of naïve, pre-pubertal children with growth hormone deficiency (GHD). These results are being presented by George Bright, MD, Versartis Vice President of Clinical Development, during the clinical poster session, "Growth and GH: Diagnostic Issues and Treatment" from 1:00 – 3:00 p.m. CDT today at the 16th International Congress of Endocrinology and The Endocrine Society's 96th Annual Meeting and Expo (ICE/ENDO 2014) in Chicago, IL.
Sign-up for Versartis Presents Positive Six Month VRS-317 Phase 2a Clinical Study Results investment picks
SAN RAFAEL, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Sarah Cannon Research UK today announced a collaboration to enroll patients in an ongoing Phase 3 clinical trial of its PARP inhibitor, BMN 673, for the treatment of hereditary breast cancer with a BRCA mutation.
Sign-up for Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation investment picks
Results will be announced on Tuesday, September 16 in Washington, D.C. BOSTON , Aug.
Sign-up for InspireMD to Announce Results of CGuard™ CARENET Trial at the TCT Innovation Session on Late Breaking Early Human Clinical Studies investment picks
HOUSTON , June 23, 2014 /PRNewswire/ -- The Burzynski Research Institute, Inc. (BRI) announced today that U.S. Food and Drug Administration (FDA) has notified the company that its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections has been lifted.
Sign-up for Burzynski Research Institute, Inc. Announces Lifting of the FDA Partial Clinical Hold - Phase 3 Clinical Study Agreed Upon investment picks
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) ( www.BSDMedical.com ), a leading provider of medical systems that utilize heat therapy to treat cancer, today reported initiation of a Phase I/II study (HYPROSAR) using hyperthermia, delivered using either the BSD-2000 Hyperthermia System (BSD-2000) or the BSD-500 Hyperthermia System (BSD-500), combined with proton radiotherapy to treat patients with unresectable soft tissue sarcoma.
Sign-up for BSD Medical Hyperthermia Reports Initiation of Clinical Study Using Hyperthermia and Proton Therapy to Treat Patients with Soft Tissue Sarcoma investment picks
MIGDAL HA'EMEQ, Israel, July 7, 2014 (GLOBE NEWSWIRE) -- Enzymotec Ltd.
Sign-up for Enzymotec Ltd. Announces Publication of Clinical Study Results on Crying Reduction Following Usage of INFAT(R) in Infants investment picks
http://media.marketwire.com/attachments/201106/27974_TITANlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1132380&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
Sign-up for Titan Pharmaceuticals Announces First Patient Enrollment in Clinical Study of Probuphine for Opioid Dependence investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Clinical Research Study
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Clinical Research Programs  |  Next: Clinical Results